Graph takes few seconds to load...
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.
Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing’s and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
| Annual Data | Millions of US $ except per share data | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|
| Cash on hand | $118.39 | $163.88 | $14.19 | $12.15 |
| Receivables | $1.38 | $1.92 | $0.73 | $0.07 |
| Inventory | - | - | - | - |
| Pre-Paid Expenses | - | - | - | - |
| Other Current Assets | $2.48 | $0800000 | $0.10 | $0.04 |
| Total Current Assets | $123.34 | $166.68 | $15.17 | $12.37 |
| Property, Plant, And Equipment | $6.46 | $4.23 | $0.40 | $0.22 |
| Long-Term Investments | - | - | - | - |
| Goodwill And Intangible Assets | - | - | - | - |
| Other Long-Term Assets | $0.58 | $0.50 | $0.03 | $0.01 |
| Total Long-Term Assets | $7.04 | $4.73 | $0.43 | $0.23 |
| Total Assets | $130.38 | $171.42 | $15.60 | $12.60 |
| Total Current Liabilities | $8.34 | $7.93 | $0.90 | $0.89 |
| Long Term Debt | - | - | - | $0.16 |
| Other Non-Current Liabilities | $0.05 | $3.27 | $0.02 | $0.01 |
| Total Long Term Liabilities | $4.90 | $3.27 | $29.72 | $17.91 |
| Total Liabilities | $13.24 | $11.19 | $30.62 | $18.80 |
| Common Stock Net | $210.79 | $203.54 | $0100000 | $0400000 |
| Retained Earnings (Accumulated Deficit) | $-93.80 | $-43.38 | $-16.27 | $-7.11 |
| Comprehensive Income | - | - | - | - |
| Other Share Holders Equity | $0.15 | $0.06 | - | - |
| Share Holder Equity | $117.14 | $160.23 | $-15.02 | $-6.20 |
| Total Liabilities And Share Holders Equity | - | - | - | - |
